Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome
RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...
Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines
Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an...
LianBio Board Turns Down Concentra Biosciences Buyout Offer
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not...
Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal
Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate...
Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement
China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics,...
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese...
RemeGen Ltd Receives FDA Clearance for MSLN-Targeting ADC RC88 in Gynecological Tumors
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical clearance...
China Announces New Hospital Inspection Measures to Standardize Healthcare System
The National Health Commission (NHC), in collaboration with the National Administration of Traditional Chinese Medicine...
MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers
US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership...
Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma
Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors...
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service...
Konruns Pharmaceutical Gets NMPA Approval for KC1036 Clinical Study in Juventus sarcoma
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...
Staidson Pharmaceutical’s BDB-001 Earns Breakthrough Therapy Designation in China for AAV Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that its...
3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...
Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China
China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...
Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions
Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with...
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...
China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...
Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market
Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...